BriaCell Therapeutics (BriaCell Therapeutics) LT-Debt-to-Total-Asset : 0.00 (As of Jan. 2024)

View and export this data going back to . Start your Free Trial

What is BriaCell Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. BriaCell Therapeutics's long-term debt to total assests ratio for the quarter that ended in Jan. 2024 was 0.00.

BriaCell Therapeutics's long-term debt to total assets ratio stayed the same from Jan. 2023 (0.00) to Jan. 2024 (0.00).

BriaCell Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for BriaCell Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics LT-Debt-to-Total-Asset Chart

BriaCell Therapeutics Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.30

BriaCell Therapeutics Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

BriaCell Therapeutics LT-Debt-to-Total-Asset Calculation

BriaCell Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jul. 2023 is calculated as

LT Debt to Total Assets (A: Jul. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Jul. 2023 )	/	Total Assets (A: Jul. 2023 )
	=	0	/	27.164
	=

BriaCell Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jan. 2024 is calculated as

LT Debt to Total Assets (Q: Jan. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jan. 2024 )	/	Total Assets (Q: Jan. 2024 )
	=	0	/	12.231
	=

BriaCell Therapeutics (NAS:BCTX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

BriaCell Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics (BriaCell Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

BCT:Canada

Address

235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1

Website

https://www.briacell.com

BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

Executives

Jamieson Bondarenko	director	402-1 SCOTT ST.`, TORONTO A6 M5E 1A1
Jane A Gross	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Rebecca Taub	director	750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gadi Levin	officer: CFO & Secretary	MOSHAV AZRIEL 108, LEV HASHARON L3 4582500
Priore Giuseppe Del	officer: Chief Medical Officer	44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Williams V. Williams	director, officer: President & CEO	620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083
Martin E. Schmieg	director	201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103
Miguel A. Lopez-lago	officer: Chief Scientific Officer	2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130
Vaughn C. Embro-pantalony	director	P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0
Marc Lustig	director	4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3